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Abstract
A case of a 25-year-old female with NET deriving from Meckel’s diverticulum is described. 
The patient had a one-year history of dermatological skin problems. Ultrasound examination of the abdomen, performed because of arterial 
hypertension, revealed multiple hepatic lesions, which was confirmed in contrast-enhanced CT. The typical contrast-enhanced metastatic 
lesions in CT and elevated levels of chromogranin A suggested NET of unknown origin. SRS with 99mTc-HYNICTOC was perform for 
primary tumor localisation, revealing liver and paraaortic lymph node metastases but no sign of primary tumour location. As a next step 
for primary tumour localisation 68Ga-DOTATATE PET/CT was performed, which revealed a focus of increased uptake in the small intestine, 
considered to be the primary tumour site. The imaging and clinical history of patient was discussed on TeleNEN (a novel model for the 
application of telemedicine in management of NEN). Due to the location of the primary tumour in the small intestine with no anatomical 
changes in CT, laparotomy guided with gamma probe after 68Ga-DOTATATE injection was performed. During the surgery procedure, 
the primary tumour was hardly palpable in the tip of Meckel’s diverticulum, confirmed by gamma probe. After surgery, tandem peptide 
receptor radionuclide therapy (PRRT) was started. The patient received four doses of 90Y/177Lu-DOTATATE with total activity of 360 mCi 
(13.32 GBq). The three-month follow-up 68Ga-DOTATATE PET/CT showed stable disease in the patient. 
The presented case shows the importance of the role of a multidisciplinary team cooperating in patient management. Use of RGS is essential 
in cases like the one presented, when the tumour cannot be localised only by surgical palpation. (Endokrynol Pol 2018; 69 (3): 313–317)
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Abstrakt
W pracy przedstawiono przypadek 25-letniej kobiety z nowotworem neuroendokrynnym (NET) wywodzącym się z uchyłka Meckela. 
Pacjentka od roku była leczona dermatologicznie ze względu na występujące problemy skórne. Z powodu nadciśnienia tętniczego prze-
prowadzono badanie ultrasonograficzne, które ukazało liczne zmiany w wątrobie. Wynik ten został potwierdzony w tomografii kompu-
terowej (CT) z kontrastem. Typowe zmiany przerzutowe w obrazie CT oraz podwyższone stężenie chromograniny A sugerowały NET 
o nieznanym punkcie wyjścia. W celu zlokalizowania punktu wyjścia nowotworu wykonano scyntygrafię receptorów somatostatynowych 
(SRS) z 99mTc-HYNICTOC, w której wykryto przerzuty w wątrobie i okołoaortalnych węzłach chłonnych, jednak nie znaleziono punktu 
wyjścia nowotworu. Kolejnym krokiem w poszukiwaniu punktu wyjścia nowotworu było wykonanie badania 68Ga-DOTATATE PET/CT, 
które ukazało ognisko zwiększonego wychwytu w jelicie cienkim, będące prawdopodobnym punktem wyjścia nowotworu. Zwołano 
ENETS Tumor Board, na którym przedyskutowano wyniki przeprowadzonych badań obrazowych oraz historię choroby pacjentki. Jako 
że w miejscu lokalizacji guza pierwotnego w jelicie cienkim nie widać było odpowiadającej zmiany anatomicznej w CT, przeprowadzo-
no laparotomię pod kontrolą śródoperacyjnej sondy gamma z wykorzystaniem 68Ga-DOTATATE. Odnaleziono prawie niewyczuwalny 
guz pierwotny w końcowej części uchyłka Meckela. Po zabiegu wdrożono celowaną terapię radioizotopową analogami somatostatyny 
(PRRT). Pacjentka otrzymała 4 dawki 90Y/177Lu-DOTATATE o całkowitej aktywności 360 mCi (13,32 GBq). Po trzech miesiącach wykonano 
kontrolne badanie 68Ga-DOTATATE PET/CT, które wykazało stabilny stan zmian chorobowych u pacjentki.
Przypadek ten został zaprezentowany w celu ukazania niezwykle istotnej roli jaką odgrywa współpraca zespołu wielodyscyplinarnego 
w leczeniu pacjentów. W momencie gdy zlokalizowanie guza niemożliwe jest wyłącznie za pomocą palpacji chirurgicznej, kluczową rolę 
odgrywa wykorzystanie izotopowej sondy śródoperacyjnej (RGS) podczas zabiegu tak, jak w prezentowanym przypadku. (Endokrynol 
Pol 2018; 69 (3): 313–317)
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Introduction
Neuroendocrine tumours (NETs) are neoplasms that 
can synthesise, store, and release bioactive compounds. 
The most common localisation of NETs is the gastro-
intestinal tract. They are usually silent, which leads 
to very late diagnosis, when distant metastases are 
present. 30% of patients present the signs of carcinoid 
syndrome [1]. This is characterised most commonly by 
the abdominal pain (63%), diarrhoea (40%), weight loss 
(33%), and flushing (13%) [2]. 
NETs can originate from uncommon sites, which 
can lead to clinical confusion, delayed diagnosis, and 
inappropriate treatment. One of the less common locali-
sations is Meckel’s diverticulum. A study on a group of 
13,715 patients with neuroendocrine tumours reported 
Meckel’s diverticulum as a localisation only in 0.48% of 
cases overall and in 0.74% if only gastrointestinal tract 
is concerned [3].
Somatostatin receptor scintigraphy (SRS) is very 
useful for primary tumour location due to overexpres-
sion of somatostatin receptor by the majority of NETs. 
Previously 111In-DTPA-pantetreotide (®Octreoscan, Ma-
lincrodt) was used with mean sensitivity 80% [4, 5] and 
99mTc-HYNICTOC (®Tektrotyd, Polatom) with sensitivity 
80–82%, specificity 69–92%, positive predictive value 
92–98%, negative predictive value 47%, and accuracy 
79–82% [6, 7]. The increasing availability of positron 
emission tomography (PET) led to the introduction 
of somatostatin analogues labelled with 68Ga, which 
became an indispensable part of the NET diagnosis 
with mean sensitivity 90.9% and specificity 90.6% in 
meta-analysis [8].
In the majority of NETs surgical treatment of the pri-
mary tumour is very important. Radioguided surgery 
(RGS) uses a radiation detection probe to localise the 
tumour. According to Kaemmerer et al., RGS with 
68Ga-labeled somatostatin analogues allows detection 
of nearly two times more of NET lesions comparing 
with surgical palpation and in 56% of cases leads to 
a change of surgical procedure [9].
Case report
A 25-year-old female with a one-year history of derma-
tological skin problems, like flushing and acne, diar-
rhoea, eyelid oedema, and lacrimation, was referred 
to the nuclear medicine department with suspicion of 
NET of unknown origin. 
Because of arterial hypertension 200/120 mmHg 
with tachycardia up to 120/min, the patient was re-
ferred for ultrasound (US) examination of the abdo-
men, which revealed multiple hepatic lesions. The next 
diagnostic step, abdominal CT examination, showed 
multiple hepatic lesions previously seen in US, with 
typical enhancement for NETs in the arterial phase, and 
several mesenteric lymph nodes, but no characteristic 
sign of primary tumour location. The typical contrast 
enhanced metastatic lesions in CT and elevated levels 
of chromogranin A (163.32 ng/ml; reference range 
 0–98 ng/ml) suggested NET of unknown origin. 
The patient was therefore referred to the nuclear 
medicine department. SRS with 99mTc-HYNICTOC 
was performed. SRS revealed multiple focal hepatic 
lesions and two paraaortic lymph nodes with over-
expression of somatostatin receptors but still no sign 
of primary tumour location (Fig. 1). Ultimately, liver 
biopsy confirmed the diagnosis of NET G1. Since SRS 
had not shown the primary tumour site, further exami-
nation — 68Ga-DOTATATE PET/CT — was performed. 
Figure 1. 99mTc-HYNICTOC whole-body scan and SPECT/CT showing liver metastasis and paraaortic lymph node. Physiological 
distribution of radiopharmaceutical in rest of the liver, spleen, and urinary bladder. Injection of radiotracer in the right forearm
Rycina 1. W badaniu po podaniu 99mTc-HYNICTOC całego ciała oraz SPECT/CT widoczne są przerzuty do wątroby i okołoaortalnych 
węzłów chłonnych. Fizjologiczne gromadzenie radiofarmaceutyku w śledzionie, pęcherzu moczowym. W prawym przedramieniu miejsce 
wstrzyknięcia radioznacznika
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It revealed previously known multiple metastases and 
paraaortic lymph nodes (SUVmax 14.5–97.5), as well 
as a new focal lesion of increased uptake in the small 
intestine (SUVmax 28.6), considered to be the primary 
tumour site, and focal lesions in both ovaries (SUVmax 
12.1 and 14.1) (Fig. 2). Examinations carried out during 
the patyient’s stay in the Division of Endocrinology 
showed highly increased levels of chromogranin A 
(> 1500 µg/l, reference range < 125 µg/l) and serotonin 
(1637 ng/ml, reference range 70–270 ng/ml) in blood 
and urinary excretion of 5-hydroxyindole acetic acid 
(5-HIAA) (61 mg/24h, reference range 2–9 mg/24h). 
Carcinoid syndrome was diagnosed. 
In such a diagnostic statement, therapy with long- 
-acting somatostatin analogue (Lanreotide: ®Somatuline 
Autogel, Ipsen) was started.
The clinical history of patient and imaging was dis-
cussed on TeleNEN Tumor Board (a novel model for the 
application of telemedicine in management of NEN). 
The modern TeleNEN platform is online consultations 
between the doctors most experienced in NEN patient 
care allow us to continually expand our knowledge, 
which is particularly important in tumors with such 
a diverse clinical course. The radiologist confirmed 
no visible anatomical changes in the small intestine, 
so classical surgery was not possible. According to the 
guidelines of the Polish Network of Neuroendocrine 
Tumours, due to the location of the primary tumour in 
the small intestine, gamma probe-guided surgery was 
taken into consideration [10]. Based on previous expe-
rience, the treatment plan included tandem peptide 
receptor radionuclide therapy (PRRT) three months 
after the surgery of the primary tumour [11]. 
The patient was directed to the surgical department 
of the Medical University of Warsaw with gamma probe 
surgery of NET experience. She underwent laparotomy 
guided with gamma probe (Sonda Neo 2000) after 
80 MBq 68Ga-DOTATATE injection. During the surgery 
procedure, the primary tumour was hardly palpable in 
the tip of Meckel’s diverticulum but clearly detected by 
gamma probe. Additionally, three hard, enlarged, mes-
enteric lymph nodes corresponding to lymph drainage 
from Meckel’s diverticulum were resected, and a small 
Figure 3. Post-surgical appearance of tumour from Meckel’s 
diverticulum
Rycina 3. Preparat pooperacyjny guza z uchyłka Meckela
Figure 2. 68Ga DOTATATE PET/CT showed multiple liver metastasis and paraaortic lymph node, which in part correspond with 99mTc- 
-HYNICTOC examination. On MIP (maximal image projection) additional foci in the intestine and pelvis was shown
Rycina 2. W badaniu 68Ga DOTATATE PET/CT widoczne są liczne przerzuty w wątrobie oraz okołoaortalnych węzłach chłonnych, 
które częściowo odpowiadają lokalizacji zmian w badaniu 99mTc-HYNICTOC. Na MIP (maximal image projection) widoczne dodatkowe 
ogniska w jelicie (punkt wyjścia) i miednicy
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left ovary section was taken. The histopathological 
examination showed NET G1 of the Meckel’s diver-
ticulum pT3, N1, Mx, with focal angioinvasion and 
three metastatic lymph nodes; no malignancy in the 
ovary was recognised. After the surgery, the patient’s 
condition was stable. The postoperative period was 
uncomplicated. The long-acting somatostatin analogue 
was continued after surgery. 
Three months later the patient started tandem 
Peptide Receptor Radionuclide Therapy (PRRT) with 
90Y/177Lu-DOTATATE according to the previously 
described protocol [16]. Between October 2016 and 
May 2017 patients received four doses of 90Y/177Lu- 
-DOTATATE with total activity of 360 mCi (13.32 GBq) 
with amino-acid infusion for nephroprotection. The last 
dose was reduced to 60 mCi (2.22 GBq) due to decreas-
ing of WBC to 1.8 x 109/l. The rest of the laboratory tests 
during the therapy were stable.
At the beginning of therapy ambulatory blood 
pressure monitoring (ABPM) was performed: mean 
24-hour blood pressure (BP) was 104/69 mmHg — day 
BP 107/71 mmHg, and night BP 96/63 mmHg. Diurnal 
urinary excretion of catecholamine metabolites were 
within normal range — 717 ug/24 hours. 
Both before and after the administration of radio-
nuclide, facial and chest flushing were presented, with 
a slightly more intensive attack during the first few 
hours after each dose. The patient complained of in-
significant nausea due to amino acid administration; 
however, no vomiting was observed. The symptoms 
were relieved by ondansetron. 
The patient underwent three months of follow-up, 
which included clinical, biochemical, and hormonal 
tests as well as 68Ga-DOTATATE PET/CT. 
Clinical symptoms of carcinoid syndrome are still 
present but are less intensive. Levels of chromogranin 
A (279 µg/l) and serotonin (735.5 ng/ml) are significantly 
lower, but measurements of 5-HIAA are in the same 
range (63 mg/24h). 
68Ga-DOTATATE PET/CT examination has shown 
the patient to be stable.
Disscusion
The unique characteristic of NETs with the presence of 
somatostatin receptors allows us to localise even small 
tumours (especially located in the intestine) intraope-
ratively using a gamma probe. This technique is indis-
pensable in the localisation of NETs that are difficult 
to find by palpation during traditional surgery, and it 
offers the immediate localisation of the primary NET. 
The use of gamma probes in oncology began in 
1949 when Selverstone et al. employed a Geiger-Muller 
probe counter for tumour localisation during brain 
surgery [12]. But the real rise in their use dates as far back 
as the ninetieth century. Nowadays we use numerous 
radiotracers not only for mapping the sentinel lymph 
node but also, as in our case, for the localisation of the 
primary lesions. 68Ga-labelled peptides are especially 
useful in the localisation of the primary tumour site. 
Radioguided surgery is considered to be a useful 
tool in localisation of NETs even as small as 0.5 cm. 
A study analysing the feasibility of RGS showed that 
it is especially valuable in the small intestine and mes-
enteric lymph nodes, where the correct identification 
of lesions reaches 81% [13]. In the same study 8.6% of 
lesions detected by gamma probe were neither possible 
for palpation nor visualisation by the surgeon [13]. 
Because the only curative method for gastrointesti-
nal NETs is surgery it is really important to define the 
number and extent of lesions. It allows a radical surgery, 
which reduces recurrence and improves the quality of 
the patient’s life. 
As in all methods, the intraoperative use of gamma 
probe can have some limitations. The main limitation 
of the probe is its dependence on the positioning and 
therefore on the operator’s skills. In some cases, high 
background activity due to the physiological uptake 
might be another problem. In some localisations of the 
tumours, e.g. the tail of the pancreas, it can hinder or 
even prevent tumour detection by the probe [13, 14]. 
Another problem could be the short half-life of the 
isotope used for that RGS, especially in cases of recur-
rence of diseases where the reoperation area may be 
hindered by adhesions. The optimum injection time 
has not yet been established because gamma camera 
reading can be done both too early and too late, dis-
rupting the result. 
The presented case shows the importance of the 
role of multidisciplinary team cooperation in patient 
management. Use of RGS is essential in cases like the 
one presented, in which the tumour cannot be localised 
only by surgical palpation.
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